

PREVALENCE OF METABOLIC SYNDROME AND RISK FACTORS KARIÑA ETHNICITY, BOLIVAR STATE, VENEZUELA

Deymar Quiroz¹, Deynalía Quiroz¹, Francisco J. Bognanno², Melania Marin²

ABSTRACT

Metabolic Syndrome includes the association of risk factors: hypertension, obesity, dyslipidemia and insulin resistance, which increases the possibility of developing cerebrovascular, cardiovascular and diabetes diseases.

General objective: To determine the prevalence of the Metabolic Syndrome and its risk factors in individuals of the Kariña ethnic group. May 2013 - May 2014.

Methods: An observational, descriptive study and cross section study was conducted; with a universe of 203 individuals, and a sample of 120 individuals (18-85 years) of the Kariña ethnic group of the Community of Mayagua, Bolívar State, Venezuela.

In all participants, the lipid profile was analyzed with the colorimetric method. The glycemia was quantified with a glucometer prior to fasting for 12 hours. The diagnostic criteria of the International Diabetes Federation, the Latin American Diabetes Association and the Adult Treatment Panel III were used.

Results: the prevalence of the metabolic syndrome was 46,67% according to the International Diabetes Federation, 39,17% Latin American Diabetes Association, and 38,33% Adult Treatment Panel II, the Kappa (k) concordance between Adult Treatment Panel III and International Diabetes Federation indicates a considerable concordance force, said Index between Adult Treatment Panel III and Latin American Diabetes Association denotes an almost perfect match strength as does the index between Latin American Diabetes Association and International Diabetes Federation.

Conclusion: A high prevalence of metabolic syndrome was found by both the Latin American Diabetes Association, International Diabetes Federation and Adult Treatment Panel III criteria, with predominance in the female gender and individuals over 50 years old.

INTRODUCTION

Metabolic Syndrome associates a group of risk factors: arterial hypertension, obesity, dyslipidemia and Insulin Resistance (related to increased body fat and lack of physical activity), which increase the probability of developing cerebrovascular and cardiovascular diseases, and diabetes¹⁻³.

In 1998, The World Health Organization (WHO) describes this syndrome by the presence of Diabetes type 2, alterations of glucose tolerance, insulin resistance, or fasting hyperglycemia, coinciding with at least two of the following criteria such as blood pressure $\geq 140/90$ mmHg; triglycerides ≥ 150 mg/dl or High Density Lipoprotein-cholesterol (HDL) < 35 mg/dl for men and < 39 mg/dl for women; waist-hip ratio $> 0,90$ for men and $> 0,85$ for women; Body Mass Index (BMI) > 30 kg/m²; microalbuminuria ≥ 20 μ g/min or albumin-creatinine ratio ≥ 30 mg/g_{4,5}. The Asociación Latinoamericana de Diabetes (ALAD) established that abdominal girth > 94 cm for men and > 88 cm for women, makes Metabolic Syndrome diagnosis. In

addition, life style, ethnicity and urbanization influenced in the high incidence of this syndrome. In Latin America, it's expected to reach 14% in the next 10 years⁸. In Zulia-Venezuela State, one study determined that one-fourth of above 20 year-old population have obesity, and one-third Metabolic syndrome⁹. Health, Education and production conventional system have been modified by oilfield exploitation and urbanization¹⁰. Due to indigenous groups, health has changed over time, which has been associated to lifestyle changes given their proximity to large cities, moreover exist few researchers that document about this syndrome in Venezuelan indigenous ethnic groups; The principal motivation to do research about this topic was to determine the prevalence of Metabolic syndrome in this group of people.

MATERIALS AND METHODS

It was performed a cross-transversal and descriptive study in Mayagua community, Orinoco Parish church, Heres borough, Bolívar-Venezuela

¹ Medical Surgeon, Health Sciences School Dr. "Francisco Battistini Casalta", University of Oriente, Núcleo Bolívar,

² Internal Physician, Department of Internal Medicine, University Hospital Ruiz y Páez, Bolívar City, Bolívar State, Venezuela.

Correspondence to:

Deymar Quiroz
deymardla053@gmail.com
Telf. y celular: 0593991608447/
0593993722775

Keywords: obesity, hyperglycemia and dyslipidemia.

Received for publication:

December, 14 2016

Accepted for publication:

July, 14 2018

Cite as:

Rev Cient Cienc Med
2018;20(1):7-20

Abreviatures used in this scientific paper:

*IDF: International Diabetes Federation

**ATP III: Adults Treatment Panel III

***ALAD: Asociación Latinoamericana de Diabetes

*BP: Blood Pressure

**PAS: Blood Pressure Systolic

***PAD: Blood Pressure Diastolic

°cHDL: cholesterol high density lipoproteins

°°DM2: Diabetes Mellitus type 2

State. The universe is formed by 203 Kariñas between 18-85 years old with direct ancestry, from which was decided to sample 120 (59,1% of Kariña population) individuals using the following formula:

$$n = \frac{N\sigma^2 Z^2}{(N-1)e^2 + \sigma^2 Z^2};$$

Where: n=sample size; N=population size; σ =Population Standard Deviation, it was used a constant value of 0,5; Z=confidence levels, it was employed 95% of confidence that is equal to 1,96; e=Margin of error with a value of 6% (0,06).

The inclusion criteria involves: Kariña ethnic group individuals, male and female sex of direct ancestry between 18-85 years old. The exclusion criteria includes, indigenous from a different ethnic group ancestry, pregnant women, diagnosis of endocrine-metabolic diseases, Metabolic syndrome, Diabetes Mellitus and Cushing's syndrome.

The materials used were: an aneroid sphygmomanometer (Lane Aneroid CEO123), stethoscope, (Littmann Brand Classic II S.E.), tape measure (1,50cm), sterile gloves, cotton, syringe of 5cc, scalpel n°21, tubes with red end caps, Blood-Glucose Monitoring System (SUMASENSOR SXT CEO123), Blood-Glucose Biosensor (SUMASENSOR SXT) and sterile lancets for single use only (LIANFA 28G).

To the recollection data was necessary an informed consent form, in which identification data, genre, ethnicity, waist circumference, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were registered.

The lipid profile which includes total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL) and triglycerids were obtained through a blood sample analyzed with the colorimetric method. Blood sugar levels were quantified with a glucometer, a 12-hour fast was required. The criteria of ATP III, IDF and ALAD (see Table 1) were applied to determine the prevalence of Metabolic syndrome¹¹.

The Statistical analysis was made by SPSS® 23 program (versión 23; Statistical Package for the Social Sciences, SPSS Inc, Chicago, IL). Tables and figures were made in Microsoft Excel® 2010 program. Data were analyzed throughout descriptive statistics as the mean, standard deviation, minimum and maximum value, absolute and relative frequencies.

The normality of variables were assessed by the Kolmogorov-Smirnov test. Due to, evaluated variables did not follow the normal distribution, were assessed with the Chi-squared test. The confidence interval was 95% and the differences are statistically significant with a $p \leq 0,05$. To assess the concordance between ALAD, International Diabetes Federation (IDF), Adult Treatment Panel III (ATP III) criteria, the Cohen's kappa coefficient was applied and a scale that express the force of concordance qualitatively was used to interpret it. According to Landis and Koch, it is considered: no agreement, a Kappa coefficient (k) of 0,00; slight, a Kappa coefficient (k) between 0,01-0,2; fair 0,21-0,40; moderate 0,41-0,60; 0,61-0,80 as substantial; 0,81-1,0 as almost perfect agreement¹².

It was obtained the average age $42,07 \pm 16,81$ years old, waist circumference $93,88 \pm 14,96$ cm, HDL $43,05 \pm 9,66$ mg/dl, triglycerides $130,98 \pm 116,55$ mg/dl, fast blood sugar $102,45 \pm 19,03$ mg/dl, SBP $120,75 \pm 14,68$ mmHg y DBP $81,17 \pm 13,36$ mmHg.

According to IDF, the abdominal obesity frequency is 77% (n=92), (male sex 39% [n=47] y female 38% [n=45]), ALAD indicates 58% (n=70) (female sex 31% [n=37] y male 28% [n=33]), ATP III mentions 47% (n=56) (female sex 31% [n=37] y male 16% [n=19]); There was not significant difference between IDF and ALAD in gender, while ATP III presents significant differences.

As stated by IDF, abdominal obesity was predominant in the 30-39 years old group with 21,7% (n=26) and ATP III with 11,7% (n=14); without significant differences at a rate of $p=0,106$ y $p=0,068$ respectively. In respect of ALAD ruled over the age group with a 15,8% (n=19) and a significant difference of ($p=0,025$).

Low levels of HDL in female was 35,8% (n=43) and 25,8% (n=31) in male, which make a significant difference. Hypertriglyceridemia was higher in men with 15,8% (n=19) compared to women with 9,2% [n=11]; Fast blood glucose ≥ 100 mg/dL more in women 24,2% (n=29) than men 23,3% (n=28), blood pressure (DBP ≥ 85 mmHg y/o SBP ≥ 130 mmHg), 23% (n=28) in men and 16% (n=19) in women. There weren't significant differences about gender for this criteria (Figure 1).

The 61,6% (n=74) of population presented low levels of HDL, it's predominant with 16,7% (n=20) in 18-29 years old age group, without significant difference ($p=0,653$); high triglycerides prevail in 30-39 (7,5% [n=9]) and 40-49 years old (7,5% [n=9]) with significant differences ($p=0,018$). Fast blood glucose ≥ 100 mg/dL is predominant 47,5% (n=57), 18-29 years old group was the most affected with 10,8% (n=13) no significant difference ($p=0,115$). The 39,1% (n=47) show DBP ≥ 85 mmHg and SBP ≥ 130 mmHg, 50-59 years group are disproportionately affected with 12,5% (n=15) and significant difference ($p=0,000$).

The prevalence of metabolic syndrome was major according to IDF 46,67% (n=56), followed by ALAD 39,17% (n=47), and finally ATP III 38,33% (n=46). In the one hand, the Kappa (k) concordance between ATP III and IDF was 0,797, which indicates a significant force of concordance; On the other hand, the Kappa (k) concordance between ATP III and ALAD was 0,912 showed an almost perfect agreement; Last, the Kappa (k) concordance between ALAD and IDF was 0,848 almost perfect agreement too (Figure 2).

In terms of prevalence of metabolic syndrome, female gender is disproportionately affected based on ALAD information 20,83% (n=25), ATP III 20,83% (n=25), while based on IDF both female and male gender are predominant

23,33%(n=28), no significantly statistics differences were found.

According to the age group we found significant differences, 50-59 years (9,2%[n=11]) are the most affected among 60 years onwards (9,2%[n=11]), reported by ALAD (p=0,045) and ATP III (p=0,016), IDF (p=0,02) is predominant in 30-39 years (10,8%[n=13]), 60 years onwards (10,8%[n=13]) for each group (Table 2).

Table 1 Clinical Diagnosis Criteria of Metabolic Syndrome¹¹

Parameters	Abdominal obesity	High tryglicerides	Low cHDL *	High PA*	Glucose metabolism alterations	Diagnosis
IDF*	Waist circumference ≥90cm in men y ≥80cm in women (Asian and Latin American)	> 150 mg/dl (or in specific lipid lowering treatment)	< 40mg/dl in men or < 50 mg/dl in women	PAS** ≥130 mm Hg y/o PAD*** ≥ 85 mm Hg or antihypertensive treatment	fasting glycemia ≥100 mg/dL or DM2 previously diagnosed	Abdominal Obesity +2 of 4
ATP III**	Waist circumfere>102cm in men (for hispanics >94cm) y > 88cm in women	≥ 150 mg/dl (or in specific lipid lowering treatment)	(effect treatment in cHDL cHDL°)	> 130/85 mm/Hg	fasting glycemia ≥ 100 mg/dL or high glycemia treatment	3 of 5
ALAD***	Perimetro de cintura ≥94cm in men and ≥88cm in women	> 150 mg/dl (or in specific lipid lowering treatment)		PAS** ≥130 mm Hg y/o PAD*** ≥ 85 mm Hg or antihypertensive treatment	Anormal Fasting glycemia, glucose intolerance or Diabetes	Abdominal Obesity +2 of 4

Fuente: Data obtained from Latin-American Consensus of Asociación Latinoamericana de Diabetes (ALAD) 2010.

DISCUSSION

Age, various population ethnicity, lifestyle, environment, and nutritional status between countries, may have effects in prevalence of metabolic syndrome^{13,14}. In respect to waist circumference average value was 93,88±14,96 cm, higher than Waraos indigenous ethnicity (91,02±11,50 cm) mentioned by Brito et al 2013⁸ and Año indigenous Age, various population ethnicity, lifestyle, environment, and nutritional status between countries, may have effects in prevalence of metabolic syndrome^{13,14}. In respect to waist circumference average value was 93,88±14,96 cm, higher than Waraos indigenous ethnicity (91,02±11,50 cm) mentioned by Brito et al 2013⁸ and Año indigenous (89,74±15,43 cm) by Bermúdez et al 2009¹⁵, considered a criterion of abdominal obesity according to IDF, ATP III y ALAD¹¹. The relative high visceral adipose tissue amount compared with subcutaneous cellular tissue, plus high abdominal circumference in Asian and Hindu people, may explain a greater prevalence of this syndrome unlike African-American men who tend to subcutaneous fat¹⁶.


According to HDL concentration, it was obtained an arithmetic mean of 43,05±9,66 mg/dl, compared to Brito et al 2013⁸ (41±12,21 mg/dl) y Bermúdez et al 2009¹⁵ (39,1±10,6 mg/dl) in which results were higher, low levels of HDL repre-

sented a diagnostic criterion used for metabolic syndrome. In the one hand, triglycerides had an arithmetic average of 130,98±116,55 mg/dl, less than Brito et al 2013 study (135,05±65,70 mg/dl)⁸; on the other hand, fast blood glucose was 102,45±19,03 mg/dl, also representing a diagnostic criterion to metabolic syndrome¹¹, but was higher in Brito et al 2013 study⁸ (82,89±26,24 mg/dl).

There is a mean for SBP 120,75±14,68 mmHg and DBP 81,17±13,36 mmHg, similar to the reported by Brito et al 2013 (SBP 123,28±15,27 mmHg; DBP 78,11±9,67 mmHg)⁸.

Abdominal obesity is more frequent in female gender 31% than male 28% according to ALAD. ATP III show female 31% and male 16% similar to Brito et al⁸ (ALAD: female 55,9% and male 51,9%; ATP III female 61,8% and male 22,2%, in contrast IDF shows male gender as the more affected 39% compared to female 38%, which differ from Brito et al⁸ female 91,2% and male 55,6%. The Strong Heart study stablished indigenous community Pima presents higher risk of becoming obese due to 50% of adult population is obese¹⁷. In Chile, previous studies described a gradual increase prevalence of Mapuche ethnicity individuals in urban area different from rural area, it may result from an adaptation process of behaviors from their way of life to modern habits¹³. In the Cardiovascular Risk Factor Multiple Evaluation Latin America (CARMELA) scientific study, in 2008, was reported an obesity abdominal prevalence increased with age, finding similar to this study¹⁸.

Figure 1
Frequency of Metabolic syndrome components according to IDF, ALAD, and ATPIII, in function of gender indigenous of Kariña ethnicity. Mayagua, Municipality of Heres, Estado Bolívar – Venezuela, Mayo 2013 – Mayo 2014.



Source: Data obtained of clinical history made to the sample research in the Mayagua community


Table 2 Frequency of Metabolic Syndrome according to IDF, ALAD and ATPIII criteria, in function of age. Indigenous of Kariña ethnicity Municipio Heres, Estado Bolívar – Venezuela, May,2013-May,2014

IDF		Does not fulfill criteria for Metabolic Syndrome		Metabolic syndrome		Total		p
		N	%	N	%	N	%	
Age	18 - 29	24	20,0	8	6,7	32	26,7	0,02
	30 - 39	18	15,0	13	10,8	31	25,8	
	40 - 49	8	6,7	10	8,3	18	15,0	
	50 - 59	7	5,8	12	10,0	19	15,8	
	60 y más	7	5,8	13	10,8	20	16,7	
	Total	64	53,3	56	46,7	120	100,0	
ALAD		Does not fulfill criteria for Metabolic Syndrome		Metabolic syndrome		Total		p
		N	%	N	%	N	%	
Age	18 - 29	25	20,8	7	5,8	32	26,7	0,045
	30 - 39	21	17,5	10	8,3	31	25,8	
	40 - 49	10	8,3	8	6,7	18	15,0	
	50 - 59	8	6,7	11	9,2	19	15,8	
	60 y más	9	7,5	11	9,2	20	16,7	
	Total	73	60,8	47	39,2	120	100,0	
ATP III		Does not fulfill criteria for Metabolic Syndrome		Metabolic syndrome		Total		p
		N	%	N	%	N	%	
Age	18 - 29	25	20,8	7	5,8	32	26,7	0,016
	30 - 39	23	19,2	8	6,7	31	25,8	
	40 - 49	9	7,5	9	7,5	18	15,0	
	50 - 59	8	6,7	11	9,2	19	15,8	
	60 y más	9	7,5	11	9,2	20	16,7	
	Total	74	61,7	46	38,3	120	100,0	

Source: Data obtained of clinical history made to the sample research in the Mayagua community

Figure 2

Prevalence of Metabolic syndrome according to ALAD, IDF and ATP III criteria. Indigenous of Kariña Ethnicity. Mayagua, Municipality of Heres, Bolívar State - Venezuela, May 2013-May 2014.



Source: Data obtained of clinical history made to the sample research in the Mayagua community

Obesity could be one of the principal reasons of high metabolic syndrome prevalence due to, it increases with the rise in obesity, simultaneously¹⁴. Visceral or abdominal adipose tissue is active by lipolysis, tumor necrosis factor α (TNF- α), leptin, resistin, interleukin-6 (IL-6) and other substances that can develop proinflammatory state, endothelial damage or insulin resistance, because it produces an insulin sensitivity change of muscle tissue because of higher free fatty acids that cause metabolism glucose inhibition, moreover an increased lipogenesis, gluconeogenesis, VLDL, LDL and lower HDL^{19,20}. The release of free fatty acids is due to the action of catecholamines on $\beta 3$ receptor, have lipolytic activity in visceral adipose tissue²¹.

Furthermore, the release of TNF- α is able to maintain a high concentration of free fatty acids, due to stimulates fat breakdown (lipolysis) and suppress lipogenesis resulting in impaired insulin sensitivity²².

In the hyperglycemia was found a frequency of 47,50% higher than Bermudez et al 2009 (14%)¹⁵ and Brito et al 2013 (9,8%)⁸. Some indigenous population studies of Mexico reported a prevalence of diabetes mellitus 4,4% in Otomies indigenous of Querétaro; in tribes including Pima of Sonora, male 6,3% y female 10,5%; Mazatecas of Oaxaca 2,1%, and other types of metabolic disorders in tepehuana, huichol y mexicana de Durango; mayas de Yucatán and triquis de Oaxaca^{23,24}.

Prevalence of Metabolic syndrome in Kariña indigenous group is higher than Waraos⁸ and Añú¹⁵, more frequent in female gender in Añú¹⁵ and Waraos⁸ areas, CARMELA study¹⁸ and a systematic review performed by De Carvalho et al in Brazilian adults, an indigenous group of Rio Grande do Sul,

it was determined metabolic syndrome prevalence 65,3% used NCEP-ATP III (2001)²⁵ as a diagnostic criteria. Gyakobo et al performed in Ghana, a rural population study, in which metabolic syndrome was more frequent in women, taking into account IDF y NCEP ATP III criteria for diagnosis, is in line with this research paper²⁶. According to Misra, et al metabolic syndrome prevalence in Sri Lanka is higher, corresponding to men 35% and 51% are women, what this again highlights an increased frequency in women²⁷. In China, the prevalence is low between young women, but increase at middle and old age¹⁴. Metabolic syndrome is prevalent in the Andean of Peru, especially old women as reported by Medina-Lezama et al²⁸.

Metabolic syndrome was frequent in old ages similar to CARMELA¹⁸, Bermúdez et al¹⁵, Brito et al⁸ and De Carvalho et al²⁵ have mentioned. It has been shown that in most part of the world have increased the prevalence, and it's estimated about 20%-25% adult people is affected, resulting in a high rate of obesity and sedentary lifestyle²⁵.

Overall prevalence of metabolic syndrome is about 24% in white people, which increase in proportion to age, >30% people older than 50 years and 40% over the age of 60¹⁵.

The presence of Insuline resistance in patients with metabolic syndrome increase cardiovascular risk, due to VLDL becomes more atherogenic due to a rise of cholesterol esters and LDL also get this quality through oxidative modification, capacity to accumulate on intima thickness and be picked up by macrophage receptors, making easier atherosclerosis^{29,30}.

In conclusion, it was found a high prevalence of metabolic syndrome according to ALAD, IDF y ATP III criteria, female gender predominant, >50 year-old individuals, who have

high cardiovascular risk and diabetes. For this reason, we recommend to perform indigenous group ethnic research in order to document risk factors, lifestyle changes, eating habits that cause Metabolic Syndrome, cardiovascular diseases and Diabetes mellitus. So, we can foster health-promotion and disease prevention and prompt treatment to improve quality of life of indigenous population.

REFERENCES

1. Rojas E, Velasco M, Bermúdez V, Israili Z, Bolli P. **Targeting Hypertension in Patients with Cardiorenal Metabolic Syndrome.** *Curr Hypertens Rep* [Internet].2012 [Citado Marzo 2014];11(1):1-9. Disponible en: https://www.researchgate.net/publication/230588683_Targeting_Hypertension_in_Patients_with_Cardiorenal_Metabolic_Syndrome
2. Bermúdez V, Paris Marcano R, Cano C, Arráiz N, Amell A, Cabrera M, et al. **The Maracaibo City Metabolic Syndrome Prevalence Study: Design and Scope.** *American Journal of Therapeutics* [Internet].2010 [Citado en Marzo 2014];17:288-294. Disponible en: https://www.researchgate.net/publication/41001103_The_Maracaibo_City_Metabolic_Syndrome_Prevalence_Study_Design_and_Scope
3. López ME, Sosa MA, Labrousse NPM. **Síndrome Metabólico.** *Rev. posgrado Vía. Cátedra Med* [Internet].2007 [Citado en Enero 2014];174:12-15. Disponible en: http://med.unne.edu.ar/revista/revista174/3_174.pdf
4. Crepaldi G, Maggi S. **El Síndrome Metabólico: contexto histórico. Diabetes Voice** [Internet]. 2006 [Citado en Enero 2014]; 51:8-10. Disponible en: https://scholar.google.cl/scholar?cluster=16325125827136121768&hl=es&as_sdt=0,5
5. Jurado Santa Cruz F, Peralta Cordero G, Morales Sánchez M, Rodríguez Acar M, Peralta Pedrero ML. **Psoriasis y síndrome metabólico.** *Rev Cent Dermatol Pascua* [Internet].2013;22(2):50- Disponible en: <http://www.medigraphic.com/pdfs/derma/cd-2013/cd132b.pdf>
6. Lizarzaburu Robles JC. **Síndrome metabólico: concepto y aplicación práctica.** *An Fac med* [Internet].2013 [Citado en Abril 2014];74(4):315-320. Disponible en: <http://www.scielo.org.pe/pdf/afm/v74n4/a09v74n4.pdf>
7. Ríos García AL, Alonso L M, Carmona Z, Cabana Jiménez AD, Martínez Orellano R. **Frecuencia y factores de riesgo para el desarrollo del síndrome metabólico en pacientes del programa de obesidad de una institución de salud en Barranquilla (Colombia), 2011.** *Salud Uninorte Barranquilla* [Internet].2013 [Citado en Enero 2014];29(2):315-326. Disponible en: <http://www.redalyc.org/pdf/817/81730430016.pdf>
8. Brito N, Córcega A, Marín M, Bognanno JF, Alcázar RJ, Pérez K. **Frecuencia de Síndrome Metabólico en Indígenas de la Etnia Warao de Barrancas del Orinoco, Estado Monagas, Venezuela.** *Rev Venez Endocrinol Metab* [Internet].2013 [Citado en Enero 2014];11(3):128-140. Disponible en: <http://www.saber.ula.ve/bitstream/123456789/37945/1/articulo3.pdf>
9. Viso M, Rodríguez Z, Aponte L, Barboza A, Barreto P, Villamizar M, et al. **Insulinorresistencia, obesidad y síndrome metabólico. Cohorte CDC de Canarias en Venezuela.** *Salus* [Internet].2013 [Citado en Enero 2014];17(1):18-24. Disponible en: <http://www.redalyc.org/html/3759/375933972005/>
10. Freire G, Villalón ME, Biord H, Scaramelli F, Tarble K, Perera MA, et al. **Salud indígena en Venezuela. Ministerio del Poder Popular para la Salud** [Internet]. 2007 [Citado en 2014];(2):7-239. Disponible en: https://books.google.cl/books?hl=es&lr=&id=xLLIKgjetkYC&oi=fnd&pg=PR2&dq=salud+indigena+en+venezuela&ots=Zsgnqe1wMA&sig=gjC9SyQ_VsRBAXjVCNH8tbmxgv0#v=onepage&q=salud%20indigena%20en%20venezuela&f=false
11. Sinay I, Costa Gil J, De Loreda L, Ramos O, Lúquez H, Da Silva Filho RL, et al. **Epidemiología, Diagnóstico, Control, Prevención y Tratamiento del Síndrome Metabólico en Adultos. Consenso Latinoamericano de la Asociación Latinoamericana de Diabetes (ALAD)** [Internet].2010 [Citado en Marzo 2014];XVIII(1):25-44. Disponible en: <http://www.revistaalad.com/pdfs/100125-44.pdf>
12. Landis JR, Koch GG. **The Measurement of Observer Agreement for Categorical Data.** *International Biometric Society* [Internet].2013 [Citado en Noviembre 2014];33(1):159-174. Disponible en: <http://www.jstor.org/stable/2529310>
13. Philco P, Serón P, Muñoz S, Navia P, Lanás F. **Factores asociados a síndrome metabólico en la comuna de Temuco, Chile.** *Rev Med Chile* [Internet].2012 [Citado en Marzo 2014];140:334-339. Disponible en: <http://www.scielo.cl/pdf/rmc/v140n3/art08.pdf>
14. Cai H, Huang J, Xu G, Yang Z, Liu M, et al. **Prevalence and Determinants of Metabolic Syndrome among Women in Chinese Rural Areas.** *PLoS ONE* [Internet].2012 [Citado en Noviembre 2014];7(5):1-1. Disponible en: <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0036936>
15. Bermúdez P, Valmore J, Finol G, Freddy J, Leal N, Parra V, et al. **Prevalencia del síndrome metabólico en la población adulta Añu de la laguna de Sinamaica del municipio Páez, estado Zulia.** *Revista Latinoamericana de Hipertensión.* [Internet].2009 [Citado en Marzo 2014];4(3):63-70. Disponible en: <http://www.redalyc.org/pdf/1702/170216837002.pdf>
16. Eckel RH. **Síndrome metabólico.** En: Fausi AS, Braunwald E, Kasper DL, Hauser EL, Longo DL, Jameson JL, et al. *Harrison Principios de Medicina Interna.* 17a ed. México: McGraw-Hill Interamericana; 2009.p.1509-1514
17. Chacín M, Rojas J, Pineda C, Rodríguez D, Núñez Pacheco M, Márquez Gómez M, et al. **Predisposición humana a la Obesidad, Síndrome Metabólico y Diabetes: El genotipo Ahorrador y la incorporación de los diabetógenos al genoma humano desde la Antropología Biológica.** *Síndrome Cardiometabólico* [Internet].2011 [Citado en Marzo 2014];1(1):11-24. Disponible en: https://www.researchgate.net/publication/249011664_Predisposicion_humana_a_la_Obesidad_Sindrome_Metabolico_y_Diabetes_El_genotipo_Ahorrador_y_la_incorporacion_de_los_diabetogenos_al_genoma_humano_desde_la_Antropologia_Biologica
18. Escobedo J, Schargrósky H, Champagne B, Silva H, Boissonnet CP, Vinuesa R, et al. **Prevalence of the Metabolic Syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study.** *Cardiovascular Diabetology* [Internet].2009 [Citado en Marzo 2014];8:52. Disponible en: https://www.researchgate.net/publication/26837956_Prevalence_of_the_Metabolic_Syndrome_in_Latin_America_and_its_association_with_sub-clinical_carotid_atherosclerosis_The_CARMELA_cross_sectional_study
19. Albornoz López R, Pérez Rodrigo I. **Nutrición y síndrome metabólico.** *Nutr clín diet Hosp* [Internet].2012 [Citado en Enero 2014];32(3):92-97. Disponible en: http://www.nutricion.org/publicaciones/revista_2012_32_3/NUTRICION.pdf
20. Bresciani Salaroli L, Dias Saliba RA, Zandonade E, Bisi Molina M, Souza Bissoli N. **Prevalence of metabolic syndrome and related factors in bank employees according to different defining criteria, Vitória/ES, Brazil.** *CLINICS* [Internet].2013 [Citado en Noviembre 2014];68(1):69-74. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552453/>

21. Rojas J, Bermudez V, Leal E, Aparicio D, Peña G, Acosta I, et al. **Origen étnico y enfermedad cardiovascular.** Archivos Venezolanos de Farmacología y Terapéutica [Internet].2008 [Citado en Marzo 2014];27(1):41-58. Disponible en: https://www.researchgate.net/publication/233967188_Origen_etnico_y_enfermedad_cardiovascular
22. Acosta García E. **Vigencia del Síndrome Metabólico.** Acta bioquím clin Latinoam [Internet].2011 [Citado en Enero 2014];45(3):423-430. Disponible en: <http://www.redalyc.org/pdf/535/53521520003.pdf>
23. Bojorges Velázquez LA, Castillo Herrera CJA, Jiménez Tamayo R. **Factores de riesgo de síndrome metabólico en estudiantes de la universidad Pablo Guardado Chávez, año 2013.** Rev Cubana Invest Bioméd [Internet].2013 [Citado en Marzo 2014];32(4):379-388. Disponible en: http://scielo.sld.cu/scielo.php?pid=S0864-03002013000400001&script=sci_arttext&tlng=pt
24. Herrera Huerta EV, García Montalvo EA, Méndez Bolaina E, López López JG, Valenzuela OL. **Sobrepeso y obesidad en indígenas nahuas de Ixtaczoquitlán, Veracruz, México.** Rev Perú Med Exp Salud Pública [Internet].2012 [Citado en Marzo 2014];29(3):345-349. Disponible en: <http://www.scielo.org.pe/pdf/rins/v29n3/a08v29n3.pdf>
25. De Carvalho Vidigal F, Bressan J, Babio N, Salas Salvadó J. **Prevalence of metabolic syndrome in Brazilian adults: a systematic review.** BMC Public Health [Internet].2013 [Citado en Noviembre 2014];13:1198. Disponible en: <http://www.biomedcentral.com/1471-2458/13/1198>
26. Gyakobo M, Amoah A, Martey Marbell D, Snow R. **Prevalence of the metabolic syndrome in a rural population in Ghana.** BMC Endocrine Disorders [Internet].2012 [Citado en Noviembre 2014];12:25. Disponible en: <http://www.biomedcentral.com/1472-6823/12/25>
27. Misra A, Misra R, Wijesuriya M, Banerjee D. **The metabolic syndrome in South Asians: Continuing escalation & possible solutions.** Indian J Med Res [Internet].2007 [Citado en Noviembre 2014];125:345-354. Disponible en: <http://icmr.nic.in/ijmr/2007/March/0310.pdf>
28. Medina Lezama J, Zea Diaz H, Morey Vargas O, Bolaños Salazar JF, Muñoz Atahualpa E, et al. **Prevalence of the metabolic syndrome in Peruvian Andean hispanics: The PREVENCIÓN study.** Elsevier [Internet].2007 [Citado en Noviembre 2014];78:270-281. Disponible en: https://scholar.google.cl/scholar?cluster=14081083358573048114&hl=es&as_sdt=0,5
29. Soca PEM. **Mecanismos del riesgo cardiovascular en el síndrome metabólico.** Rev Fed Arg Cardiol [Internet].2013 [Citado en Febrero 2014];42(3):166-167. Disponible en: <http://www.fac.org.ar/1/revista/13v42n3/editor/edit02/soca.pdf>
30. Fernández SL, Rueda Clausen CF, Pradilla LP, López Jaramillo P, Lahera V. Participación de la Angiotensina II en el desarrollo de la enfermedad aterosclerótica. Rev. Med [Internet].2006 [Citado en Marzo 2014];14(1):8-18. Disponible en: <http://www.redalyc.org/html/910/91014103/>